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The novel positive-contrast magnetic resonance imaging (MRI) marker C4 consists of an aqueous solution of cobalt chloride
(CoCl
2
) complexed with the chelator N-acetylcysteine (NAC). We evaluated whether the presence of C4 or its components would
produce reactive oxygen species (ROS, including hydroxyl, peroxyl, or other reactive oxygen species) in cultured cells. Human
cancer or normal cells were incubated with 1% (w/v) CoCl
2
⋅6H
2
O or 2% NAC or a combination of both (1% CoCl
2
⋅6H
2
O : 2%
NAC in an aqueous solution, abbreviated as Co :NAC) in the presence or absence of H
2
O
2
. Intracellular ROS levels were measured
and quantified by change in relative fluorescence units. Student’s 𝑡-tests were used. In all cell lines exposed to 1000𝜇M H
2
O
2
, the
Co :NAC led to ≥94.7% suppression of ROS at 5 minutes and completely suppressed ROS at 60 and 90 minutes; NAC suppressed
ROS by ≥76.6% at 5 minutes and by ≥94.5% at 90 minutes; and CoCl
2
⋅6H
2
O suppressed ROS by ≥37.2% at 30 minutes and by
≥48.6% at 90 minutes.These results demonstrate that neither Co :NAC nor its components generated ROS; rather, they suppressed
ROS production in cultured cells, suggesting that C4 would not enhance ROS production in clinical use.
1. Introduction
Prostate cancer is the most common type of cancer among
men in the United States [1]. Low-dose-rate brachytherapy
is a treatment option for men with low-risk or favorable
intermediate-risk prostate cancer, providing cure rates sim-
ilar to those of intensity-modulated radiation therapy [2, 3]
more cost-effectively and with less severe declines in bowel
health–related quality of life [4]. Oncologic outcomes and
treatment-related toxicity after low-dose-rate brachytherapy
depend greatly on the quality of the implant, which in turn
depends on accurate placement and dose distribution of
the radioactive seeds. Quality assurance efforts traditionally
rely on computed tomography, which visualizes radioactive
titanium seeds well but is not optimal for visualizing soft
tissues such as the prostate and surrounding tissues.Magnetic
resonance imaging (MRI) visualizes soft tissues well [5, 6]
but requires a positive-contrast marker to precisely identify
radioactive seeds [7].
Cobalt in its ionized form (Co2+ or Co(II)) has param-
agnetic properties that generate positive-contrast signals on
T1-weighted MRI. We developed an MRI marker in which
cobalt chloride (CoCl
2
) is complexed with 6 water molecules
(H
2
O) and the chelating antioxidantN-acetylcysteine (NAC).
The resulting “cobalt complex contrast aqua solution,” or
“C4,” is being tested for use inMRI-guided seed implantation
in men undergoing brachytherapy for prostate cancer [7].
We have verified that the C4 MRI marker can improve
visualization and localization of implanted radioactive seeds
during and after implantation, and we are exploring its use to
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improve quality assurance and assessment of effectiveness in
brachytherapy [8].
Cobalt is a naturally occurring element. In humans, a
single cobalt atom is the central metal component of vitamin
B
12
, a cofactor and activator of several essential enzymes that
is present in most tissues, chiefly in the liver [9]. Although
vitamin B
12
is essential for erythrocyte formation, protein
metabolism, and central nervous system function, cobalt and
its related compounds can induce oxidative stress [10–12].
Cobalt ions have been observed to generate reactive oxygen
species (ROS) in vivo and in vitro, and CoCl
2
has been shown
to induce the formation of hydroxyl radicals (∙OH) from
hydrogen peroxide (H
2
O
2
) [13]. Thus, the US Department of
Health and Human Services established a minimal risk level
for cobalt (0.01mg/kg/day) [9].
The potential toxicity caused by the inadvertent release
of cobalt in C4 from temporarily or permanently implanted
medical devices is unknown. To reduce the potential body
burden of C4 cobalt, we chelated cobalt with NAC, which
is known to increase both urinary and fecal excretion of
cobalt and decrease cobalt levels in the liver and spleen [14].
The purpose of the current study was to test whether the
components of C4, individually or in combination, would
produce reactive oxygen species including hydroxyl and
peroxyl in cultured cells.
2. Materials and Methods
2.1. Cell Cultures. The human prostate cancer cell line PC3
and the human normal tongue cell line Hs-680Tg were
obtained from the American Type Culture Collection (Man-
assas, VA, USA). The human head and neck cancer cell
line HN5 was supplied by Dr. Jeffrey Myers (University of
Texas MD Anderson Cancer Center, Houston, TX, USA).
HN5 and Hs-680Tg cells were maintained in DMEM/F-12
medium (Corning Cellgro, Mediatech, Inc., Manassas, VA,
USA). PC3 cells were maintained in RPMI-1640 medium
(Sigma-Aldrich, St. Louis, MO, USA). All culture media were
supplemented with 10% fetal bovine serum (FBS, Sigma-
Aldrich), 100U/mL penicillin, and 100 𝜇g/mL streptomycin
(Gibco, Thermo Fisher, Grand Island, NY, USA). Cells were
grown as monolayers in 75 cm2 flasks and maintained in
a humidified 5% CO
2
/95% air atmosphere at 37∘C. The
identities of all cell lines were confirmed by genotyping (STR
profiling) at MD Anderson’s Characterized Cell Line Core
Facility (NCI Core Grant CA016672).
2.2. Intracellular ROS Assay. Intracellular ROS levels were
measured by using OxiSelect Intracellular ROS Assay Kits
(Cell Biolabs, San Diego, CA, USA), which can be used to
measure the activity of ROS (hydroxyl, peroxyl, and other
reactive oxygen species) within a cell, according to the man-
ufacturer’s instructions. The assay uses the cell-permeable
fluorogenic probe 2󸀠,7󸀠-dichlorodihydrofluorescein diacetate
(DCFHDA), which upon diffusion into cells is deacetylated
by cellular esterases to form a nonfluorescent compound
that is then rapidly oxidized by ROS to create highly flu-
orescent 2󸀠,7󸀠-dichlorodihydrofluorescein (DCF). The green
fluorescence intensity is proportional to the ROS levels within
the cytosol [15]. The effects of antioxidants or free radical
compounds on DCFHDA can be measured in terms of rel-
ative fluorescence units (RFUs). Fluorescence was measured
with a VICTOR X3 multilabel plate reader (PerkinElmer,
Inc., Wentzville, MO, USA) at excitation and emission wave-
lengths of 485 nmand 535 nm, andRFUswere quantifiedwith
PerkinElmer 2030 software.
2.3. Preparation of Reagents and Test Solutions. Opti-MEM
(Phenol Red-negative) medium (Gibco) without FBS was
used to prepare the working solution of 1000 𝜇M H
2
O
2
(diluted from an 882mM H
2
O
2
stock [Thermo Fisher Sci-
entific, Waltham, MA, USA]), the serial dilution of DCF to
generate standard curves, and the 1x working solution of
DCFHDA (diluted from a 20x stock supplied in the ROS
Assay Kit). All the above solutions were protected from light
and used immediately upon dilution. Test materials included
cobalt chloride hexahydrate (CoCl
2
-6H
2
O, Fluka Sigma-
Aldrich 60820, Lot 1313139) and N-acetylcysteine (NAC,
Sigma-Aldrich 47250-1006, Lot 051M1820V).The ingredients
were dissolved in distilled water to create weight by volume
percentage (w/v%, where 1% = 1 g/100mL) concentrations
for use. Stock solutions of 10% CoCl
2
6H
2
O, 20% NAC, and
10% CoCl
2
⋅6H
2
O : 20% NAC (Co :NAC [10% : 20%]) were
prepared. Final concentrations of 1% CoCl
2
⋅6H
2
O, 2% NAC,
and Co :NAC (1% : 2%, i.e., C4) were used to treat cells in
FBS-free Opti-MEM (Phenol Red-negative) medium.
2.4. ROS Staining and Quantification. Each cell sample was
assayed in triplicate. Cells were counted with a TC 20 Auto-
mated Cell Counter (Bio-Rad Laboratories, Inc., Hercules,
CA, USA). A specific number of cells (for HN5, 5 × 103
cells/well; for Hs-680Tg, 8 × 103 cells/well; and for PC3, 1 ×
104 cells/well, all cells in 100 𝜇L culture medium) were plated
in clear-bottom black 96-well cell-culture plates and cultured
for 24 hours. Cells were thenwashedwith phosphate-buffered
saline (PBS, Corning Cellgro) 3 times before 100 𝜇L of the
1x (for HN5 and Hs-680Tg cells) or 0.5x (for PC3 cells)
DCFHDA/FBS-free Opti-MEMmedium solution was added
to each well. Plates were then incubated at 37∘C for 30
minutes. The 1x DCFHDA/FBS-free Opti-MEM medium
solution was then removed and the cells were washed 4
times with PBS. After the final wash, 90 𝜇L of FBS-free Opti-
MEM medium, or 90𝜇L of 1000 𝜇M H
2
O
2
FBS-free Opti-
MEMmedium solution, was added to each well. Immediately
thereafter, 10 𝜇L of the 10% CoCl
2
⋅6H
2
O, or the 20% NAC, or
the Co :NAC (10% : 20%)was added to eachwell according to
the different treatment conditions, and cells were incubated
at 37∘C.The plates were read and fluorescence was quantified
before and at different times (5, 30, 60, and 90 minutes) after
treatment. ROS content was reported as RFUs.
2.5. Cell Morphology Analysis. Each cell sample was assayed
in triplicate. Cells were counted with a TC 20 Automated Cell
Counter (Bio-Rad Laboratories, Inc., Hercules, CA, USA).
A specific number of cells (for HN5, 5 × 103 cells/well;
for Hs-680Tg, 8 × 103 cells/well; and for PC3, 1 × 104
cells/well, all cells in 100 𝜇L culture medium) were plated
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in clear 96-well cell-culture plates overnight and then cells
were treated with the greatest clinical exposure concentration
(i.e., if 120 markers [the maximum number likely to be used
in one patient with a prostate volume of 60 cc] were to
leak simultaneously into the human periprostatic area after
implantation) of C4 or its components (1% CoCl
2
⋅6H
2
O,
or the 2% NAC, or the Co :NAC [1% : 2%]), and cells were
incubated at 37∘C. At 90 minutes after treatment, pictures of
cells were taken with a bright field Evos XL core microscope
(AMEX 1000, Life Technologies, Carlsbad, CA, USA) at ×10
magnification.
2.6. Statistical Analyses. Each experiment was repeated at
least three times. Data are presented as means ± standard
error of the mean (SEM). Student’s 𝑡-tests (unpaired, unequal
variance) were used to compare two groups of independent
samples for ROS expression. 𝑃 < 0.05 was considered to
indicate statistical significance.
3. Results
3.1. Changes in ROS Levels in the Absence of H
2
O
2
3.1.1. Changes in ROS Levels under Control Conditions. The
absolute change in RFU values for the different treatment
conditions was defined as the RFUs after treatment minus
the RFUs before treatment. In the absence of H
2
O
2
or any
treatment, intracellular ROS levels began to increase slightly
at 5 minutes and remained high at 60 minutes (for PC3 cells,
29,893 [±4087] at 5min versus 47,169 [±5451] at 60min; for
Hs-680Tg cells, 15,817 [±945] at 5min versus 30,366 [±5002]
at 60min; and for HN5 cells, 22,501 [±2753] at 5min versus
46,577 [±8787] at 60min) and at a similar level at 90 minutes
for all three cell lines (Figure 1).
3.1.2. Changes in ROS Levels after Treatment with 1%
CoCl
2
⋅6H
2
O. Compared with the untreated control con-
dition, intracellular ROS levels in cells treated with 1%
CoCl
2
⋅6H
2
O began to decrease as early as 5 minutes after
treatment and remained at similar levels thereafter in all
three cell lines (for PC3 cells, 11,329 [±930] at 5min versus
12,404 [±935] at 90min; for Hs-680Tg cells, 5570 [±494] at
5min versus 8987 [±998] at 90min; and for HN5 cells, 9645
[±1385] at 5min versus 16,159 [±1336] at 90min) (𝑃 < 0.001
versus control for all). At 5 minutes after treatment with 1%
CoCl
2
⋅6H
2
O, the ROS levels were 37.9% of the control level
in PC3 cells, 35.2% of the control level in the Hs-680Tg cells,
and 42.9% of the control level in the HN5 cells (Figure 1).
3.1.3. Changes in ROS Levels after Treatment with 2% NAC.
Intracellular ROS levels in cells treated with 2% NAC were
substantially lower than in the control condition (𝑃 < 0.001
for all, in all three cell lines; for PC3 cells, 9046 [±927] at 5min
versus 5571 [±446] at 90min; for Hs-680Tg cells, 4396 [±113]
at 5min versus 3388 [±458] at 90min; and forHN5 cells, 7238
[±1147] at 5min versus 5487 [±604] at 90min). At 5 minutes
after treatment with 2% NAC, ROS levels were 30.3% of the
control level in the PC3 cells, 27.8% of the control level in the
Hs-680Tg cells, and 32.2%of the control level in theHN5 cells
(Figure 1).
3.1.4. Changes in ROS Levels after Treatment with Co : NAC
(1% : 2%). Treatment with Co :NAC (1% : 2%) led to very
small amounts of intracellular ROS at 5 minutes after treat-
ment (PC3 cells, 1432 [±478]; Hs-680Tg cells, 277 [±90]; and
HN5 cells, 1945 [±645]); by 60 and 90 minutes, intracellular
ROS levels dropped to undetectable levels in all three cell
lines. At 5min after treatmentwithCo :NAC,ROS levelswere
4.8% of the control level for PC3 cells, 1.8% of the control level
for Hs-680Tg cells, and 8.6% of the control level for HN5 cells
(𝑃 < 0.001 versus control for all) (Figure 1).
3.2. Changes in ROS Levels in the Presence of H
2
O
2
3.2.1. In the Presence of H
2
O
2
(1000 𝜇M). Untreated cells
showed a slight increase in intracellular ROS levels relative to
control cells (withoutH
2
O
2
) at 5minutes. Notably, ROS levels
greatly increased with time in all three cell lines thereafter
(at 90 minutes: for PC3 cells, 123,613 [±12,494], 255.9% of the
control level; for Hs-680Tg cells, 172,750 [±18,681], 543.2% of
the control level; and for HN5 cells, 174,291 [±14,274], 352.0%
of the control level; 𝑃 < 0.001 for all) (Figure 1).
3.2.2. Changes in ROS Levels after Treatment with 1%
CoCl
2
⋅6H
2
O. In the presence of H
2
O
2
(1000 𝜇M), treatment
with 1% CoCl
2
⋅6H
2
O led to similar intracellular ROS levels
in all three of cell lines at 5 minutes compared with the no
treatment group. Beginning at 30 minutes and continuing
to 90 minutes, intracellular ROS levels dropped significantly
relative to the untreated condition (with H
2
O
2
only) in
all three cell lines (at 90 minutes: for PC3 cells, 63,547
[±6240], 51.4% of untreated condition; for Hs-680Tg cells,
67,711 [±4988], 39.2% of untreated condition; and for HN5
cells, 79,249 [±6015], 45.5% of untreated condition; 𝑃 < 0.05
for all). However, these values were significantly higher than
those treated with 1% CoCl
2
⋅6H
2
Owithout H
2
O
2
in all three
cell lines at all 4 measurement points (for PC3 cells, 306.3% at
5min versus 512.3% at 90min; for Hs-680Tg cells, 574.6% at
5min versus 753.4% at 90min; and for HN5 cells, 330.3% at
5min versus 490.4% at 90min; 𝑃 < 0.001 for all) (Figure 1).
3.2.3. Changes in ROS Levels after Treatmentwith 2%NAC. In
the presence of H
2
O
2
(1000 𝜇M), treatment with 2%NAC led
to ROS levels that were similar to those after 2%NACwithout
H
2
O
2
and remained quite low over time in all three cell lines
(at 90 minutes: for PC3 cells, 6774 [±617]; for Hs-680Tg cells,
4760 [±231]; and for HN5 cells, 6278 [±727]). These ROS
levels were significantly lower than in the untreated condition
(withH
2
O
2
only) (for PC3 cells, 23.4% of untreated condition
at 5min versus 5.5% of untreated condition at 90min; for Hs-
680Tg cells, 18.5%of untreated condition at 5min versus 2.8%
of untreated condition at 90min; and for HN5 cells, 21.7%
of untreated condition at 5min versus 3.6% of untreated
condition at 90min; 𝑃 < 0.001 for all) (Figure 1).
3.2.4. Changes in ROS Levels after Treatment with Co : NAC
(1% : 2%). Treatment of cells with Co :NAC (1% : 2%) in the
4 Journal of Toxicology
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Figure 1: Changes in intracellular reactive oxygen species (ROS) levels over time in response to various treatment conditions. Human prostate
cancer cells (PC3, (a)), human normal tongue cells (Hs-680Tg, (b)), and human head and neck cancer cells (HN5, (c)) were treated with
components of the novel MRI positive-contrast marker C4 as follows: 1% [w/v] CoCl
2
⋅6H2O, 2% [w/v] N-acetylcysteine (NAC), or the
combined Co :NAC solutions (1% : 2% [w/v]), in the presence or absence of 1000𝜇M H
2
O
2
. At 5, 30, 60, or 90 minutes after treatment,
intracellular ROS levels were evaluated. Controls (Con) are cells not treated and not exposed to H
2
O
2
. The ROS levels were measured in
terms of relative fluorescence units (RFUs) at excitation and emission wavelengths of 485 nm and 535 nm. Values shown are means ± SEM
from at least 3 independent experiments. Student’s 𝑡-tests (unpaired, unequal variance) were used for comparisons.
presence of H
2
O
2
(1000𝜇M) led to very small amounts of
intracellular ROS at 5min (similar to levels in the Co :NAC
without H
2
O
2
condition) in all three cell lines (for PC3 cells,
2100 [±573]; for Hs-680Tg cells, 175 [±119]; and for HN5 cells,
1009 [±404]). These levels were considerably lower than the
untreated condition (with H
2
O
2
only) at 5min (for PC3 cells,
5.3% of the untreated condition; for Hs-680Tg cells, 0.7%
of the untreated condition; and for HN5 cells, 3.1% of the
untreated condition; 𝑃 < 0.001 for all) and further decreased
over time to reach undetectable levels at 60 and 90 minutes
in all three cell lines studied (Figure 1).
3.3. Cell Morphology under Treatment. Compared with un-
treated cells, there was no histopathologic evidence of
changes in cell morphology at 90 minutes after treatment
with the greatest clinical exposure concentration of C4 or
its components (1% CoCl
2
⋅6H
2
O, or the 2% NAC, or the
Co :NAC [1% : 2%]) (Figure 2).
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Figure 2: Cell morphology after various treatment conditions. Human prostate cancer cells (PC3), human normal tongue cells (Hs-680Tg),
and human head and neck cancer cells (HN5) were treated with the greatest clinical exposure concentration of the novel MRI Co :NAC
positive-contrast agent for C4marker or its components (1% [w/v] CoCl
2
⋅6H2O, 2% [w/v]N-acetylcysteine (NAC), or the combinedCo :NAC
solutions (1% : 2% [w/v])). At 90 minutes after treatment, cell morphology pictures were taken with a bright field Evos XL core microscope
(AMEX 1000, Life Technologies, Carlsbad, CA, USA) at ×10 magnification. Controls (Con) were untreated cells.
4. Discussion
In this study, we used a well-established ROS assay, which
can be used to measure ROS (hydroxyl, peroxyl, and other
reactive oxygen species) activity within a cell, to evaluate the
influence of C4 and its components on the intracellular levels
of ROS. The maximum tolerance concentration (1000𝜇M)
for H
2
O
2
(i.e., that which does not lead to cell death within
24 hours) that could induce the highest levels of ROS in
cells was used. We measured ROS levels over time (at 5, 30,
60, and 90 minutes after treatment) within human prostate
cancer PC3 cells, human normal tongue Hs-680Tg cells, and
human head and neck cancer HN5 cells after treatment with
1%CoCl
2
⋅6H
2
O, or 2%NAC, or the combined formCo :NAC
(1% : 2%), in the presence or absence of H
2
O
2
. Standard
curves were used as a quality control in these experiments.
We found that one of the components of the MRI positive-
contrast marker C4 (2% NAC) drastically suppressed both
background ROS and the ROS in the presence of H
2
O
2
in
all three cell lines at all of the tested times (𝑃 < 0.001 for
all).The other component of C4 (1% CoCl
2
) also significantly
suppressed both background ROS levels (𝑃 < 0.001 for
all) and the ROS in the presence of H
2
O
2
at 30, 60, and
90 minutes after treatment in all three cell lines (𝑃 < 0.05
for all). Notably, the C4 marker itself (Co : NAC [1% : 2%])
drastically suppressed both basal and H
2
O
2
-related ROS
levels as early as 5 minutes after treatment (𝑃 < 0.001 for all)
and reduced ROS levels to undetectable levels at 60 and 90
minutes in all three cell lines. Moreover, no cell morphology
change was observed at 90 minutes after cells were exposed
to the greatest clinical exposure concentration of C4 or its
components. These findings suggest that patients given C4
for seed localization during MRI-guided brachytherapy are
not at risk of enhanced ROS generation from the presence of
Co(II) in the C4 complex.
Ionized cobalt [Co2+, or Co(II)] can generate ROS [10–
12] in cultured cells. ROS can induce direct cellular injury,
which triggers a cascade of radical reactions enhancing
secondary ROS generation. Excessive generation of ROS
may further stimulate inflammatory processes involving
secretion of chemotactic factors, growth factors, proteolytic
enzymes, lipoxygenases, and cyclooxygenase, leading to the
inactivation of antiproteolytic enzymes and the release of
signaling proteins [12]. ROS is also generated by the for-
mation of coordination complexes with metals and some
chelating agents [16]. Previous reports have demonstrated
that chelation of Co(II) can change its oxidation potential
[17–19]. Mello-Filho and Meneghini and Sugiyama et al.
investigated ∙OH radical generation by Co(II) in the presence
of chelators such as B-alanyl-3-methyl-L-histidine (anserine)
and 1,10-phenanthroline and deferoxamine [20, 21]. Mao et
al. reported that the extent of Co(II)-mediated generation
of ROS from H
2
O
2
depended on the properties of chelators
[19], but they did not evaluate NAC. In the creation of C4,
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we chose NAC as the agent to block ROS from Co(II),
because NAC has anti-ROS activity and can also function
as an ROS inhibitor [22, 23]. In the current study, the
presence of 2% NAC drastically suppressed H
2
O
2
-related
ROS in HN5 cells (by up to 96.4%), Hs-680Tg cells (by up
to 97.2%), and PC3 cells (by up to 94.5%) at 5–90 minutes
after treatment. These findings are consistent with another
report from Zou and colleagues [24]. The greater relevance
to our study was their finding that treatment with NAC
significantly inhibited CoCl
2
-induced apoptosis via blocking
ROS production. Similarly, Jung and Kim [25] also found
that NAC attenuated ROS levels induced by CoCl
2
in the
PC12 cells. Notably, when the MRI-compatible marker C4
itself (Co : NAC [1% : 2%]) was administrated, the ROS at
the presence of H
2
O
2
in HN5, Hs-680Tg, and PC3 cells
was suppressed to undetectable levels starting at 30 minutes
(for HN5 and Hs-680Tg cells) or at 60 minutes (PC3) after
treatment. Collectively, this evidence supports the safety of
the MRI marker C4 for clinical use in terms of the risk of
generating ROS from interactions of Co(II) with H
2
O
2
.
In the current study, we observed to our surprise that 1%
CoCl
2
⋅6H2O, one of the components of the MRI-compatible
marker C4, could also reduce background ROS levels in all
three cell lines. Even though there was H
2
O
2
-related ROS
generation in the presence of 1% CoCl
2
⋅6H2O, those ROS
levels were significantly decreased in HN5 cells (by up to
55.4%), Hs-680Tg cells (by up to 60.8%), and PC3 cells (by
up to 51.5%) over time (30–90 minutes after treatment).
Our study did have limitations, since the conclusionswere
based on the investigation of one human prostate cancer, one
human normal tongue, and one human head and neck cancer
cell line under different treatment conditions. Further studies
with more cell lines and in vivo models are warranted.
5. Conclusions
Weconclude that, in human prostate cancer PC3 cells, human
normal tongue Hs-680Tg cells, and human head and neck
cancer HN5 cells, significant DCFH oxidation does not occur
in the presence of CoCl
2
or NAC alone or in combination;
and induced (by the presence of H
2
O
2
) DCFH oxidation is
blocked by CoCl
2
and NAC and by Co :NAC.These findings
provide support for the safe use of C4, in which 1% of
the component CoCl
2
⋅6H
2
O is complexed with 2% of the
chelating antioxidantNAC as a positive-contrastMRImarker
for men with prostate cancer undergoing brachytherapy.
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